←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Antisense Oligonucleotides
Brett Monia
PhD
🏢Ionis Pharmaceuticals🌐USA
Chief Executive Officer
70
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Brett Monia is CEO of Ionis Pharmaceuticals and has long led the oncology ASO program including the development of AZD9150 (danvatirsen) targeting STAT3. His work has driven the translation of antisense oligonucleotides as cancer therapies. He is a senior figure in cancer ASO therapeutics.
Share:
🧪Research Fields 研究领域
ASO cancer therapy
STAT3 ASO
AZD9150
RNase H ASO
oncogene targeting
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Brett Monia 的研究动态
Follow Brett Monia's research updates
留下邮箱，当我们发布与 Brett Monia（Ionis Pharmaceuticals）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment